Zydus Lifesciences shares fell nearly 3% in Wednesday’s early trade after a U.S. federal judge ruled in favor of Exelixis Inc. in a patent dispute over Cabometyx, a blockbuster cancer drug. MSN Laboratories, which had partnered with Zydus Lifesciences, conceded that its generic version of Cabometyx infringed on three of Exelixis’ patents. As a result, MSN will be blocked from launching its generic version of the drug until the patents expire in January 2030.
In a major setback for Zydus Lifesciences, the ruling means that MSN, its partner, will not be able to bring the generic cancer drug to market as planned. The court’s decision upholds the validity of key patents protecting Cabometyx, dealing a blow to Zydus’ partnership with MSN in this product line.
As of 10:23 AM, Zydus Lifesciences shares were trading 3.04% lower at ₹1,026.00 on the NSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
